INHIBITORS
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
-
Update on products in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...
-
Emicizumab rollout well underway
Montreal, December 16, 2021 – The rollout of emicizumab (Hemlibra) in the provinces and territories served by Canadian Blood Services (CBS) is well underway. Emicizumab...
-
Novel treatments in bleeding disorders: The EHC November Review
CLICK HERE to access the November 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
CHS 2020 Annual Report
CLICK HERE to access the CHS 2020 Annual Report and the complete Financial Statements.